Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia 12Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Blast Crisis 5Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Waldenstrom Macroglobulinemia 3Neoplasms 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Graft vs Host Disease 3Dendritic Cell Sarcoma, Interdigitating 3Congenital Abnormalities 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Infliximab 3Fecal Microbiota Transplantation 3vedolizumab 2Prednisone 2Methylprednisolone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2tocilizumab 1prednylidene 1fish oil triglycerides 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Methylprednisolone Hemisuccinate 1Loperamide 1Injections 1Endoscopy 1Colonoscopy 1Cell- and Tissue-Based Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colitis × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡